| Indication |
Phase |
Sample Size |
Study
Design/Services |
| Acute Myelogenous Leukemia |
N/A |
N/A |
Preparation of an ISS and ISE for an eCTD |
| Acute Myelogenous Leukemia |
3 |
400 |
Randomized,
double-blind, multi-center, placebo-controlled, parallel group
study |
| Advanced Solid Tumors |
1 |
60 |
Open-label, dose
escalation study |
| Carcinoid Pancreatic Neuroendocrine Tumors |
2 |
200 |
Provided resources for legacy safety data
retrieval services for three Phase 2 studies |
| Colorectal Cancer |
2 |
N/A |
Multi-center,
randomized, double-blind, placebo- and active-controlled,
parallel group study/
Assisted in the study design and sample size
calculations |
| Epithelial Ovarian, Fallopian Tube or Primary
Peritoneal Carcinoma |
2 |
20 |
Open-label, fixed dose |
| GI or Lung Cancer |
1 |
80 |
Open-label,
non-randomized, dose-finding study |
| Healthy Subjects (Prostate Cancer) |
1 |
5 |
Single arm, open-label
study |
| Hematologic Malignancies |
1 |
40 |
Single-center, dose
escalation study |
| Malignant Pheochromocytoma/Paraganglioma |
2 |
60 |
Multi-national,
multi-center, single arm, open-label study |
| Malignant Pheochromocytoma/Paraganglioma |
2 |
80 |
Multi-center, single
arm, open-label study |
| Melanoma |
1 |
10 |
Single-dose, open-label
study |
| Melanoma |
2 |
80 |
Randomized, open-label
study |
| Multiple Myeloma |
4 |
40 |
Prospective,
multi-center, randomized, single- and multiple-dose, open-label
study |
| Non-Small Cell Lung Cancer |
2/3 |
200 |
Multi-center,
randomized, double-blind, placebo-controlled study |
| Ovarian Cancer |
2 |
50 |
Multi-center, parallel
group, open-label study |
| Peripheral T cell Lymphoma |
3 |
90 |
Open-label,
multi-center, single arm study |
| Prostate Cancer |
1 |
10 |
Open-label study |
| Prostate Cancer |
2 |
50 |
Multi-center, parallel
group, open-label study |
| Prostate Cancer Diagnostic Imaging |
1 |
10 |
Single-blind,
randomized, crossover design |
| Renal Cell Carcinoma |
2 |
25 |
Single-center, cohort
study |
| Renal cell carcinoma |
1 |
25 |
Open-label,
single-center, pilot study |
| Sarcoma |
2 |
10 |
Single-center, parallel
group, open-label study |
| Solid Tumors |
1 |
40 |
Two-arm, open-label,
non-randomized, dose escalation study |
| Solid Tumors |
1 |
50 |
Open-label, two-arm,
dose finding study |
| Solid Tumors |
4 |
20 |
Prospective, open-label,
randomized, multiple-dose, two-way crossover study |
| Solid Tumors or Lymphomas |
1 |
70 |
Open-label,
non-randomized, multicenter, dose escalation study |
